reformulated oxycontin (Mundipharma gmbh)
90
Structured Review
Mundipharma gmbh
reformulated oxycontin
Reformulated Oxycontin, supplied by Mundipharma gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/reformulated+oxycontin/reformulated+oxycontin/pm34649203-171-19-11
Average 90 stars, based on 1 article reviews
Reformulated Oxycontin, supplied by Mundipharma gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/reformulated+oxycontin/reformulated+oxycontin/pm34649203-171-19-11
Average 90 stars, based on 1 article reviews
reformulated oxycontin - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia Article Snippet: B.L., L.D., R.B., R.A. and M.F. have received an untied educational grant from Article Title: Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Article Snippet: MF and LD have received an untied educational grant from Article Title: To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia? Article Snippet: BL and LD have received untied educational grant funding from Article Title: Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. Article Snippet: NL, Article Title: Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. Article Snippet: Background: Out-of-pocket costs for opioid agonist treatment (OAT) constitute a barrier to treatment entry and retention.This study examines OAT clients’ total out-of-pocket costs (including dispensing fees, travel costs and OAT-related appointment costs) in different treatment settings (public clinics, community pharmacies, and private clinics).. Methods: Cross-sectional survey of 402 people with opioid drug use (OUD) in New South Wales (NSW), Victoria (VIC), Tasmania (TAS), Australia; 266 clients (66%) currently receiving methadone, buprenorphine or buprenorphine-naloxone treatment were asked about dispensing fees, travel costs and OAT-related appointment costs in the past 28 days.. A two-part regression model was used to deal with non-normal distributions of costing data (right skew and excess zeros). Article Title: A nationwide study of the extent and factors associated with fentanyl use in Australia. Article Snippet: Objective: To examine fentanyl utilisation in the Australian community and determine the geographic and socio-demographic factors associated with higher rates of fentanyl utilisation.. Methods: National sales data (supplied by IMS Health) were used to estimate fentanyl utilisation (in pack sales and milligrams) in Australia during 2013, mapped to Australian Bureau of Statistics (ABS) Statistical Local Areas (SLAs) and Remoteness Areas.. Socio-demographic characteristics and total population estimates of SLAs were obtained from the ABS. Article Title: The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons. Article Snippet: Background: Oxycodone is implicated in a large number of overdose deaths, many involving intravenous administration of preparations designed for oral administration.. International responses have included education strategies, regulatory changes, and tamper-resistant preparations to discourage injecting.. Reformulated OxyContin was introduced in Australia in April 2014 and this study examines its impact on service utilisation, defined as visits to inject drugs at the Sydney Medically Supervised Injecting Centre (MSIC) and opioid overdoses at the MSIC. Article Title: Chronic pain, pain severity and analgesia use in Australian women of reproductive age. Article Snippet: |